NASDAQ:CARA Cara Therapeutics (CARA) Stock Price, News & Analysis → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free CARA Stock Alerts $0.71 -0.02 (-3.19%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$0.70▼$0.7350-Day Range$0.53▼$1.0552-Week Range$0.50▼$4.67Volume181,886 shsAverage Volume653,295 shsMarket Capitalization$38.65 millionP/E RatioN/ADividend YieldN/APrice Target$9.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Cara Therapeutics alerts: Email Address Cara Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside1,267.3% Upside$9.75 Price TargetShort InterestBearish5.56% of Float Sold ShortDividend StrengthN/ASustainability-1.39Upright™ Environmental ScoreNews Sentiment0.54Based on 3 Articles This WeekInsider TradingSelling Shares$30,906 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.03) to ($0.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.97 out of 5 starsMedical Sector183rd out of 910 stocksPharmaceutical Preparations Industry70th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingCara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCara Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.56% of the float of Cara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCara Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cara Therapeutics has recently increased by 4.03%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCara Therapeutics does not currently pay a dividend.Dividend GrowthCara Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCara Therapeutics has received a 61.20% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Clinical research services for physical health" and "Opioid painkillers" products. See details.Environmental SustainabilityThe Environmental Impact score for Cara Therapeutics is -1.39. Previous Next 2.0 News and Social Media Coverage News SentimentCara Therapeutics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cara Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 8 people have searched for CARA on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Cara Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -79% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,906.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of Cara Therapeutics is held by insiders.Percentage Held by Institutions44.66% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Cara Therapeutics are expected to grow in the coming year, from ($1.03) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cara Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cara Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCara Therapeutics has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About Cara Therapeutics Stock (NASDAQ:CARA)Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Read More CARA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CARA Stock News HeadlinesApril 20, 2024 | usatoday.comBeing the Marquette women's basketball coach means a lot to Cara Consuegra. She's ready to rebuild.April 18, 2024 | money.usnews.comCara Therapeutics IncApril 23, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...April 15, 2024 | americanbankingnews.comCara Therapeutics, Inc. (NASDAQ:CARA) Expected to Earn FY2028 Earnings of ($0.21) Per ShareApril 14, 2024 | msn.comThe Challenge: Zach Nichols reacts to seeing Cara Maria Sorbello back for All Stars 4April 14, 2024 | msn.comThe Challenge’s Cara Maria Sorbello thought All Stars 4 castmates would reunite due to ‘hatred’ of herApril 14, 2024 | msn.comNY GOP moves to knock ‘The Biggest Loser’ trainer Cara Castronuova out of Senate primaryApril 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cara Therapeutics: Promising Prospects for Oral Difelikefalin in Notalgia Paresthetica TreatmentApril 23, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...April 11, 2024 | investing.comCara Therapeutics CMO sells shares worth over $2,000April 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cara Therapeutics Amidst Promising Korsuva Ph 2/3 Program and Market PotentialApril 2, 2024 | news.yahoo.comAshland Police Chief Cara Rossi reinstated today after two months of administrative leaveApril 2, 2024 | msn.com‘The Biggest Loser’ trainer Cara Castronuova sues NY GOP in bid for SenateApril 2, 2024 | globenewswire.comCara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 30, 2024 | yahoo.comCara Delevingne’s First Song is Really (Really!) Good: Listen HereMarch 30, 2024 | yahoo.comCara Delevingne Wears Trendy Pointy Shoes Out in LondonMarch 29, 2024 | yahoo.comCara Delevingne Just Stepped Out in the Prettiest Hairstyle for Dior’s PFW ShowMarch 28, 2024 | markets.businessinsider.comDemystifying Cara Therapeutics: Insights From 4 Analyst ReviewsMarch 17, 2024 | msn.comCara Delevingne thanks firefighters after cats rescued from her burning homeMarch 17, 2024 | msn.comCara Delevingne's Parents Spoke Out About The Heartbreaking Fire That Destroyed Her HomeMarch 17, 2024 | msn.comCara Delevingne’s Parents Reveal Probable Cause of Devastating Los Angeles House FireMarch 16, 2024 | finance.yahoo.comCARA Apr 2024 5.000 callMarch 15, 2024 | yahoo.comCara Delevingne says her 'heart is broken' after massive fire destroys California homeMarch 15, 2024 | msn.comCara Delevingne's Parents Reveal Cause of Her Devastating Los Angeles House FireMarch 15, 2024 | msn.comCara Delevingne’s parents say daughter is ‘devastated’ after LA mansion burned down, reveal cause of fireMarch 15, 2024 | nbcnews.comCara Delevingne's California home destroyed by massive fireMarch 15, 2024 | msn.comCara Delevingne’s L.A. Home Destroyed in Massive Fire in Middle of the Night: “My Heart is Broken”See More Headlines Receive CARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/04/2024Today4/23/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CARA CUSIPN/A CIK1346830 Webwww.caratherapeutics.com Phone(203) 406-3700Fax203-567-1510Employees55Year FoundedN/APrice Target and Rating Average Stock Price Target$9.75 High Stock Price Target$25.00 Low Stock Price Target$2.50 Potential Upside/Downside+1,234.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,510,000.00 Net Margins-565.21% Pretax Margin-565.21% Return on Equity-122.10% Return on Assets-89.64% Debt Debt-to-Equity RatioN/A Current Ratio4.54 Quick Ratio4.43 Sales & Book Value Annual Sales$20.97 million Price / Sales1.90 Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book0.70Miscellaneous Outstanding Shares54,660,000Free Float52,360,000Market Cap$39.92 million OptionableOptionable Beta0.70 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Christopher A. Posner (Age 54)President, CEO & Director Comp: $1.2MMr. Ryan D. Maynard (Age 55)Chief Financial Officer Comp: $511.7kDr. Joana Goncalves M.D. (Age 50)Chief Medical Officer Comp: $747.25kDr. Derek T. Chalmers D.Sc. (Age 60)Ph.D., Co-Founder & Senior Advisor Comp: $580.93kDr. Iris Francesconi Ph.D.Chief Strategy Officer & Head of Investor RelationsMr. Scott M. Terrillion (Age 61)Chief Compliance Officer, General Counsel & Corporate Secretary Comp: $689.63kMs. Beth Weinberg R.Ph.Senior Vice President of Regulatory Affairs & QAMr. Matthew MurphyManager of Investor RelationsMore ExecutivesKey CompetitorsUnicycive TherapeuticsNASDAQ:UNCYMarker TherapeuticsNASDAQ:MRKREledon PharmaceuticalsNASDAQ:ELDNProMIS NeurosciencesNASDAQ:PMNCleneNASDAQ:CLNNView All CompetitorsInsiders & InstitutionsJoana GoncalvesSold 2,753 sharesTotal: $2,284.99 ($0.83/share)Christopher PosnerSold 35,575 sharesTotal: $18,854.75 ($0.53/share)Scott TerrillionSold 7,770 sharesTotal: $4,118.10 ($0.53/share)Ryan D MaynardSold 5,488 sharesTotal: $2,908.64 ($0.53/share)Simplex Trading LLCSold 100 shares on 2/2/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CARA Stock Analysis - Frequently Asked Questions Should I buy or sell Cara Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CARA shares. View CARA analyst ratings or view top-rated stocks. What is Cara Therapeutics' stock price target for 2024? 4 Wall Street research analysts have issued 12-month price objectives for Cara Therapeutics' stock. Their CARA share price targets range from $2.50 to $25.00. On average, they predict the company's stock price to reach $9.75 in the next year. This suggests a possible upside of 1,267.3% from the stock's current price. View analysts price targets for CARA or view top-rated stocks among Wall Street analysts. How have CARA shares performed in 2024? Cara Therapeutics' stock was trading at $0.7430 on January 1st, 2024. Since then, CARA shares have decreased by 4.0% and is now trading at $0.7131. View the best growth stocks for 2024 here. When is Cara Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CARA earnings forecast. How were Cara Therapeutics' earnings last quarter? Cara Therapeutics, Inc. (NASDAQ:CARA) issued its quarterly earnings results on Monday, March, 4th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by $0.02. The biopharmaceutical company earned $3 million during the quarter, compared to analyst estimates of $2.34 million. Cara Therapeutics had a negative trailing twelve-month return on equity of 122.10% and a negative net margin of 565.21%. During the same quarter in the previous year, the business earned ($0.56) earnings per share. What ETF holds Cara Therapeutics' stock? Amplify Seymour Cannabis ETF holds 65,538 shares of CARA stock, representing 0.15% of its portfolio. What other stocks do shareholders of Cara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY). How do I buy shares of Cara Therapeutics? Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CARA) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersIs Tesla going out of business?DTI Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
